O-Gal Pathway-based Glyco-engineered Cell Construction Service

O-Gal Pathway-based Glyco-engineered Cell Construction Service

You Reliable Partner in O-Gal Pathway-based Glyco-engineered Cell Construction

O-Gal glycosylations modify collagen and high molecular weight (HMW) adiponectin. Key glycosyltransferases for collagen glycosylation include collagen β(1-O) galactosyltransferase 2 (COLGALT2) and collagen β(1-O) galactosyltransferase 1 (COLGALT1). Both enzymes add the monosaccharide Gal(β1-O) or the disaccharide Glc(α1-2)Gal(β1-O) to hydroxylysine residues after lysine hydroxylation. CD BioGlyco controls specific gene targets of O-Gal pathways to construct glyco-engineered cells. Our researchers have many years of operational experience in providing clients with comprehensive Glyco-engineered Cell Construction services.

  • Gene editing service

CD BioGlyco targets the knockout of Colgalt1 or Colgalt2 genes by clustered regularly interspaced short palindromic repeats (CRISPR-Cas9) to disrupt the enzymes required to eliminate O-glycan extension. Then, we transfect the constructs into human embryonic kidney 293 (HEK293) cells depending on the client's needs. Notably, the editing service we provide does not affect the growth and viability of the cells. We provide not only single-knockout cell construction services but also dual-knockout cell construction services.

  • Validation service

Our researchers use standard methods to deeply sequence total RNA isolated from HEK293 cells and calculate relative gene expression levels. HEK293 cells are inoculated in well plates and collected after co-transfection. We offer the following analytical services:

  • Sanger sequencing service
  • Indel detection for amplicon analysis (IDAA) service
  • Fluorescence-activated cell sorting (FACS) service

All data are analyzed by professionals for client use. Meanwhile, all of the raw data will also be delivered to the clients. If you have any questions, our after-sales team will reply to you the first time.

Fig.1 Schematic diagram of gene-editing and validation service. (CD BioGlyco)Fig.1 Schematic diagram of gene-editing and validation service. (CD BioGlyco)

Publication

Technology: Long-range PCR, Western blot, Gene editing

Journal: Metabolism

Published: 2021

Results: Knockout of the Colgalt1 gene leads to apoptosis and slowed collagen secretion in cells and living organisms. Knockout of the Colgalt2 gene is implicated in the adenosine 5'-monophosphate (AMP)-activated protein kinase (AMPK) signaling pathway, the adipocytokine signaling pathway, and lipid metabolism. The lack of the Colgalt2 gene interferes with lipid accumulation in cells. Meanwhile, knockout of Colgalt2 deficiency by gene editing inhibited adipogenesis and decreased the expression of PPARγ, a transcription factor related to adipogenesis, during adipocyte differentiation.

Fig.2 Factor design results. (Yang, et al., 2021)Fig.2 Factor design results. (Yang, et al., 2021)

Applications of O-Gal Pathway-based Glyco-engineered Cell

  • O-Gal pathway-based glycoengineering cells can be used for drug development and disease screening.
  • O-Gal pathway-based glycoengineering cell construction further expands the glycosyltransferase gene library.
  • O-Gal pathway-based glycoengineering cells play a key role in studying the pathogenesis of non-alcoholic fatty liver disease (NAFLD).

CD BioGlyco has a professional technical support team to help clients solve the problems encountered in Glycan Display. Our serious attitude and high-quality service have won a good market reputation. Moreover, we provide a high-quality Cell-based Glycan Display Array. We aspire to be your most reliable partner in the field of glycobiology. Please feel free to contact us.

References

  1. Yang, J.; et al. Collagen β(1-O) galactosyltransferase 2 deficiency contributes to lipodystrophy and aggravates NAFLD related to HMW adiponectin in mice. Metabolism. 2021, 120: 154777.
  2. Joshi, H.J.; et al. SnapShot: O-glycosylation pathways across kingdoms. Cell. 2018, 172(3): 632-632.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.